Cargando…

Cut-Off Analysis of CTC Change under Systemic Therapy for Defining Early Therapy Response in Metastatic Breast Cancer

Detection of circulating tumor cells (CTC) can distinguish between aggressive and indolent metastatic disease in breast cancer patients and is thus considered an independent, negative prognostic factor. A clear decline in CTCs is observed in patients who respond to systemic therapy. Nevertheless, CT...

Descripción completa

Detalles Bibliográficos
Autores principales:	Deutsch, Thomas M., Stefanovic, Stefan, Feisst, Manuel, Fischer, Chiara, Riedel, Fabian, Fremd, Carlo, Domschke, Christoph, Pantel, Klaus, Hartkopf, Andreas D., Sutterlin, Marc, Brucker, Sara Y., Schneeweiss, Andreas, Wallwiener, Markus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226373/ https://www.ncbi.nlm.nih.gov/pubmed/32344685 http://dx.doi.org/10.3390/cancers12041055

Ejemplares similares

HER2-targeted therapy influences CTC status in metastatic breast cancer
por: Deutsch, Thomas M., et al.
Publicado: (2020)

The Lack of Evidence for an Association between Cancer Biomarker Conversion Patterns and CTC-Status in Patients with Metastatic Breast Cancer
por: Stefanovic, Stefan, et al.
Publicado: (2020)

Circulating miR-200 family as predictive markers during systemic therapy of metastatic breast cancer
por: Fischer, Chiara, et al.
Publicado: (2022)

Circulating miR-200 Family and CTCs in Metastatic Breast Cancer before, during, and after a New Line of Systemic Treatment
por: Fischer, Chiara, et al.
Publicado: (2022)

Estrogen, progesterone, and human epidermal growth factor receptor 2 discordance between primary and metastatic breast cancer
por: Walter, Vincent, et al.
Publicado: (2020)

Molecular Subtype Conversion between Primary and Metastatic Breast Cancer Corresponding to the Dynamics of Apoptotic and Intact Circulating Tumor Cells
por: Stefanovic, Stefan, et al.
Publicado: (2019)

Impact of mRNA-Assessed Molecular Subtype Conversion, Intact and Apoptotic Circulating Tumor Cells on Survival of Metastatic Breast Cancer Patients: Proof of Principle
por: Stefanovic, Stefan, et al.
Publicado: (2020)

Measuring the Time to Deterioration for Health-Related Quality of Life in Patients With Metastatic Breast Cancer Using a Web-Based Monitoring Application: Longitudinal Cohort Study
por: Brusniak, Katharina, et al.
Publicado: (2021)

Tumor biomarker conversion between primary and metastatic breast cancer: mRNA assessment and its concordance with immunohistochemistry
por: Stefanovic, Stefan, et al.
Publicado: (2017)

An Electronic Patient-Reported Outcome Tool for the FACT-B (Functional Assessment of Cancer Therapy-Breast) Questionnaire for Measuring the Health-Related Quality of Life in Patients With Breast Cancer: Reliability Study
por: Matthies, Lina Maria, et al.
Publicado: (2019)

Reliability of an e-PRO Tool of EORTC QLQ-C30 for Measurement of Health-Related Quality of Life in Patients With Breast Cancer: Prospective Randomized Trial
por: Wallwiener, Markus, et al.
Publicado: (2017)

Do hospital type or caseload make a difference in chemotherapy treatment patterns for early breast cancer? Results from 104 German institutions, 2008–2017
por: Riedel, Fabian, et al.
Publicado: (2021)

Long-Term Patient Satisfaction and Quality of Life After Breast-Conserving Therapy: A Prospective Study Using the BREAST-Q
por: Stolpner, Ilona, et al.
Publicado: (2021)

Predictive value of neutrophil-to-lymphocyte-ratio in neoadjuvant-treated patients with breast cancer
por: von Au, Alexandra, et al.
Publicado: (2022)

Update Breast Cancer 2017 – Implementation of Novel Therapies
por: Lux, Michael P., et al.
Publicado: (2017)

Serial enumeration of circulating tumor cells predicts treatment response and prognosis in metastatic breast cancer: a prospective study in 393 patients
por: Wallwiener, Markus, et al.
Publicado: (2014)

The Brustkrebs-Studien.de website for breast cancer patients: User acceptance of a German internet portal offering information on the disease and treatment options, and a clinical trials matching service
por: Wallwiener, Markus, et al.
Publicado: (2010)

The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients
por: Wallwiener, Markus, et al.
Publicado: (2015)

Implementation of an Electronic Patient-Reported Outcome App for Health-Related Quality of Life in Breast Cancer Patients: Evaluation and Acceptability Analysis in a Two-Center Prospective Trial
por: Graf, Joachim, et al.
Publicado: (2022)

Electronic-Based Patient-Reported Outcomes: Willingness, Needs, and Barriers in Adjuvant and Metastatic Breast Cancer Patients
por: Hartkopf, Andreas D, et al.
Publicado: (2017)

Dynamic monitoring of menopause hormone therapy and defining the cut-off value of endometrial thickness during uterine bleeding
por: Sheng, Qiu, et al.
Publicado: (2016)

Analyzing non-sentinel axillary metastases in patients with T3–T4 cN0 early breast cancer and tumor-involved sentinel lymph nodes undergoing breast-conserving therapy or mastectomy
por: Riedel, Fabian, et al.
Publicado: (2020)

Simultaneous Detection of Disseminated and Circulating Tumor Cells in Primary Breast Cancer Patients
por: Hartkopf, Andreas D., et al.
Publicado: (2016)

Diagnosis and Therapy of Triple-Negative Breast Cancer (TNBC) – Recommendations for Daily Routine Practice
por: Schneeweiss, Andreas, et al.
Publicado: (2019)

Defining Obesity Cut-Off Points for Migrant South Asians
por: Gray, Laura J., et al.
Publicado: (2011)

Evaluating the influence of music at different sound pressure levels on medical students’ performance of standardized laparoscopic box training exercises
por: Nees, Lisa Katharina, et al.
Publicado: (2021)

Intravenous pamidronate versus oral and intravenous clodronate in bone metastatic breast cancer: a randomized, open-label, non-inferiority Phase III trial
por: von Au, Alexandra, et al.
Publicado: (2016)

Update Breast Cancer 2019 Part 4 – Diagnostic and Therapeutic Challenges of New, Personalised Therapies for Patients with Early Breast Cancer
por: Schütz, Florian, et al.
Publicado: (2019)

Translational Highlights in Breast and Ovarian Cancer 2019 – Immunotherapy, DNA Repair, PI3K Inhibition and CDK4/6 Therapy
por: Hartkopf, Andreas D., et al.
Publicado: (2019)

Update Breast Cancer 2019 Part 5 – Diagnostic and Therapeutic Challenges of New, Personalised Therapies in Patients with Advanced Breast Cancer
por: Welslau, Manfred, et al.
Publicado: (2019)

How previous treatment changes the metabolomic profile in patients with metastatic breast cancer
por: Nees, Juliane, et al.
Publicado: (2022)

Aneuploid CTC and CEC
por: Lin, Peter Ping
Publicado: (2018)

Defining ELISpot cut-offs from unreplicated test and control wells
por: Alexander, Neal, et al.
Publicado: (2013)

Neoadjuvant Chemotherapy of Patients with Early Breast Cancer Is Associated with Increased Detection of Disseminated Tumor Cells in the Bone Marrow
por: Volmer, Léa, et al.
Publicado: (2022)

How to define a cut-off value of tumour markers in haemodialysis patients?
por: Mercadal, Lucile, et al.
Publicado: (2009)

Impact of age on indication for chemotherapy in early breast cancer patients: results from 104 German institutions from 2008 to 2017
por: Hoffmann, Ann Sophie, et al.
Publicado: (2023)

Magnetic Particles for CTC Enrichment
por: Liu, Peng, et al.
Publicado: (2020)

Characterization of different CTC subpopulations in non-small cell lung cancer
por: Hanssen, Annkathrin, et al.
Publicado: (2016)

Recent Update Roles of Magnetic Nanoparticles in Circulating Tumor Cell (CTC)/Non-CTC Separation
por: Pipatwatcharadate, Chawapon, et al.
Publicado: (2023)

Advancing Cancer Therapy Predictions with Patient-Derived Organoid Models of Metastatic Breast Cancer
por: Önder, Cansu E., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2fi65btc230ju7gr33gjl6llj4